Literature DB >> 7246269

Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids.

B A Bengtsson, B E Malmvall.   

Abstract

Ninety patients with giant cell arteritis (GCA) were followed 3-10 years after the diagnosis. The mean observation time was 63 months. Thirteen patients died. Corticosteroids were administered to all but one patient; 35 were still on treatment after a mean observation period of 59 months. In 38 patients, 94 flare-ups of the disease were recorded during corticosteroid treatment, most of them occurring during the first year of treatment and when a low dose of prednisolone had been given. Thirty-three relapses, 76% within 3 months, occurred in 28 patients after withdrawal of treatment. One patient relapsed after more than ten years of disease. Polymyalgia rheumatica was the most common symptom of flare-up or relapse, regardless of the clinical picture at the time of diagnosis. The duration of treatment should be individualized. One year of treatment is enough in a few patients, whereas others need steroid therapy for more than four years. The rate of intercurrent disease and complications of GCA or its treatment was low. No patient developed severe eye damage due to GCA. The mortality rate was in fact lower than expected with regard to age and sex.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7246269     DOI: 10.1111/j.0954-6820.1981.tb11604.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  16 in total

1.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

2.  Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

3.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

Review 4.  Headache.

Authors:  J M Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

5.  Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study.

Authors:  S Deshayes; E Liozon; N Chanson; K Sacré; T Moulinet; C Blanchard-Delaunay; O Espitia; M Groh; M Versini; T Le Gallou; J-E Kahn; V Grobost; S Humbert; M Samson; R Mourot Cottet; K Mazodier; A Dartevel; J Campagne; A Dumont; B Bienvenu; M Lambert; A Daumas; D Saadoun; A Aouba; H de Boysson
Journal:  Clin Rheumatol       Date:  2019-01-07       Impact factor: 2.980

6.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

7.  Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).

Authors:  G Delecoeuillerie; P Joly; A Cohen de Lara; J B Paolaggi
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

8.  Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients.

Authors:  J C Mertens; G Willemsen; J L Van Saase; J H Bolk; B A Dijkmans
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

9.  Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

Authors:  M J van der Veen; H J Dinant; C van Booma-Frankfort; G A van Albada-Kuipers; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

10.  Polymyalgia rheumatica, temporal arteritis and malignancy.

Authors:  C A Speed; I Haslock
Journal:  Postgrad Med J       Date:  1995-08       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.